myelofibrosis


Also found in: Dictionary, Thesaurus, Medical, Acronyms, Wikipedia.

myelofibrosis

[‚mī·ə·lō·fī′brō·səs]
(pathology)
Growth of white, fibrous connective tissue in the bone marrow.
References in periodicals archive ?
PERSIST-1 is a randomized (2:1), open-label, multinational Phase 3 clinical trial comparing the efficacy and safety of pacritinib with that of best available therapy (BAT), other than JAK inhibitors, in 327 enrolled patients with primary and secondary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF), without exclusion for low platelet counts.
Pending completion of the acquisition, Gilead intends to initiate a pivotal Phase 3 clinical trial of CYT387 in myelofibrosis in the second half of 2013.
EXPAND: a Phase 1b, open-label, dose-finding study of ruxolitinib in patients with myelofibrosis and baseline platelet counts between 50 x 10(9)/L and 99 x 10(9)/L.
In spite of this poor prognosis, a few cases of MDS with myelofibrosis achieving a complete remission with prednisolone have been reported [19].
Identify and understand important and diverse types of therapeutics under development for Post-polycythemia vera myelofibrosis (PPV-MF).
In June, the following two potential milestone payments from Baxalta Incorporated, or Baxalta, to CTI BioPharma were accelerated in the amount of $32 million: a $12 million development milestone advance payable in connection with the potential regulatory submission to the European Medicines Agency with respect to pacritinib, which Baxalta anticipates submitting as early as late in 2015, and a $20 million development milestone advance payable for the first treatment dosing of the last patient enrolled in PERSIST-2 (the ongoing randomized Phase 3 trial evaluating pacritinib for patients with myelofibrosis whose platelet counts are less than or equal to 100,000 per microliter).
Preliminary safety and efficacy of ruxolitinib in patients with primary and secondary myelofibrosis with platelet counts of 50-100 x 10(9)/L.
We look forward to advancing the clinical trial program of pacritinib as we work to realize the full potential of this investigational compound to help patients with serious blood cancers, such as myelofibrosis.
Bruhn takes on the role of CEO at a time when Promedior is rapidly advancing its product candidates in human clinical trials for diseases involving fibrosis, including idiopathic pulmonary fibrosis (IPF), myelofibrosis, and retinal diseases.
CTI BioPharma) (NASDAQ and MTA: CTIC) and Baxter International's BioScience business (NYSE:BAX) today announced that Patient Reported Outcomes (PROs) data from the Phase 3 PERSIST-1 trial, evaluating pacritinib in patients with myelofibrosis, will be highlighted in a late-breaking oral presentation at the upcoming 20[sup.
GlobalData, the industry analysis specialist, has released its new report, Myelofibrosis Therapeutics - Pipeline Assessment and Market Forecasts to 2019.